chang tp
number share mn
price month
share price seem buoyant could
constrain patent problem
action rais target price light current
valuat also maintain neutral rate increas
forecast slightli rais ep estim factor impact
share buy-back current underway
invest overview rise expect growth sale prostat
cancer drug xtandi progress develop pipelin
posit effect share price drive valuat share price
also receiv boost increas ep approx share
buy-back howev sale profit like declin
vesicar overact bladder oab goe patent us fast
earn recov beyond mostli depend much
progress astella made drug pipelin think compani
need make good progress pipelin keep provid
sharehold return share price rise
catalysts/risk prescript drug user fee act pdufa date
complet us regulatori review gilteritinib acut myeloid
leukemia aml set novemb japanes approv
file oral roxadustat chronic kidney diseas may submit
result us phase trial women health drug
fezolinet hot flash may releas septemb term
current earn lead indic share price may much
growth achiev new prescript sale indic non-
metastat castration-resist prostat cancer pre-chemotherapi
treatment xtandi us
valuat target price base ep
previous forward price-to-earnings
price rel chart measur perform
topix close
spot exchang rate
valuat metric
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price jul upsid rate neutral target price analyst fumiyoshi sakai
profit tax
issuanc retir stock
net chang cash
number share mn
profit tax
cash equival
compani mention price
